Grace Therapeutics, Inc.
GRCE · XNASCIK 1444192fmd_046BE7F9V8X9407YSSKW7TJ4BBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Mar 01, 2015 to Sep 30, 2026, 34 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 100 | – | – | – | – |
| Cost of revenue | – | – | 0 | 0 | – | – | – | – |
| Gross profit | – | – | 0 | 100 | – | – | – | – |
| Research and development | 29 | 16 | 4 | 6 | 10 | 5 | 10 | 2 |
| Selling, general and administrative | 5 | 8 | 7 | 10 | 8 | 7 | – | – |
| Operating income | (34) | (24) | (16) | (16) | (52) | (13) | (17) | (11) |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Other non-operating income (expense) | (5) | (1) | (3) | 5 | 0 | (2) | 4 | 2 |
| Income before taxes | (39) | (26) | (20) | (10) | (52) | (15) | (13) | (9) |
| Income tax expense | 0 | 0 | 0 | (1) | (10) | (2) | (3) | (2) |
| Net income from continuing operations | (39) | (26) | (20) | (10) | (42) | (13) | (10) | (8) |
| Net income | (39) | (26) | (20) | (10) | (42) | (13) | (10) | (8) |